Evidence map›Paper›PMID 25805586›Full record

ReviewSeminars in hematology2015

The genetic landscape of diffuse large B-cell lymphoma.

Laura Pasqualucci, Riccardo Dalla-Favera

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Seminars in hematology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 86 papers.

0numbers the graph read from it
0cells of the map it votes in
86citing papers in PubMed
14.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

86 citing papers in PubMed, 174 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Review
  5. Review
  6. Liquid Biopsy in B and T Cell Lymphomas: From Bench to Bedside.International journal of molecular sciences · 2025
    Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Article
  16. Review
  17. Review
  18. Review
  19. Article
  20. Central Nervous System Lymphoma: Novel Therapies.Current treatment options in oncology · 2022
    Review

26 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Laura PasqualucciAssociate Professor of Pathology and Cell Biology, Institute for Cancer Genetics, Department of Pathology and Cell Biology, Columbia University, New York, NY. Electronic address: lp171@columbia.edu.
Riccardo Dalla-FaveraProfessor and Director, Institute for Cancer Genetics, Columbia University, New York, NY.
Cancer Genetics (United States) · USColumbia University · US

Funding

Role of MLL2 Gene Inactivation in B cell Non Hodgkin LymphomaR01CA172492 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI PASQUALUCCI, LAURA · 2013 to 2022
$3.6M
NCI NIH HHS R01 CA172492NCI NIH HHS R01CA172492
6 · The paper itself

Abstract

Diffuse large B-cell lymphoma (DLBCL), the most common lymphoid malignancy in the western world, is an aggressive disease that remains incurable in approximately 30% of patients. Over the past decade, the rapid expansion of sequencing technologies allowing the genome-wide assessment of genomic and transcriptional changes has revolutionized our understanding of the genetic basis of DLBCL by providing a comprehensive and unbiased view of the genes/pathways that are disrupted by genetic alterations in this disease, and may contribute to tumor initiation and expansion. These studies uncovered the existence of several previously unappreciated alterations in key cellular pathways that may also influence treatment outcome. Indeed, a number of newly identified genetic lesions are currently being explored as markers for improved diagnosis and risk stratification, or are entering clinical trials as promising therapeutic targets. This review focuses on recent advances in the genomic characterization of DLBCL and discusses how information gained from these efforts has provided new insights into its biology, uncovering potential targets of prognostic and therapeutic relevance.

Indexed as

B-LymphocytesCell DifferentiationGenomicsHumansLymphocyte ActivationLymphoma, Large B-Cell, DiffuseMutation

Identifiers

PMID25805586
PMCPMC4646421
OpenAlexW2148766088

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.